RNAi Therapeutics News and Research

RSS
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.
SurModics, EGEN continue collaboration on long-term controlled release of siRNA complexes

SurModics, EGEN continue collaboration on long-term controlled release of siRNA complexes

RXi Pharmaceuticals receives SBIR grant to further develop novel RNAi therapeutics

RXi Pharmaceuticals receives SBIR grant to further develop novel RNAi therapeutics

Silence strengthens RNAi IP portfolio with issuance of key patent in structural modification technology

Silence strengthens RNAi IP portfolio with issuance of key patent in structural modification technology

Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01

Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

BIND Biosciences announces $12.4 million Series C-1 financing

BIND Biosciences announces $12.4 million Series C-1 financing

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

Update on Regulus and sanofi-aventis collaboration

Update on Regulus and sanofi-aventis collaboration

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

USPTO awards Alnylam Notice of Allowance for patent covering methods of inhibiting expression of mutant genes

USPTO awards Alnylam Notice of Allowance for patent covering methods of inhibiting expression of mutant genes

Mount Sinai School of Medicine, Alnylam collaborate to develop microRNA-based attenuated influenza viruses

Mount Sinai School of Medicine, Alnylam collaborate to develop microRNA-based attenuated influenza viruses

USPTO issues patent covering methods for enhancing RNA silencing activity of RNAi agents

USPTO issues patent covering methods for enhancing RNA silencing activity of RNAi agents

RXi announces new RNAi therapeutic strategy at Jefferies 2010 Global Life Sciences Conference

RXi announces new RNAi therapeutic strategy at Jefferies 2010 Global Life Sciences Conference

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Study demonstrates protection against Ebola infection in nonhuman primates using RNAi

Study demonstrates protection against Ebola infection in nonhuman primates using RNAi

Silence Therapeutics deepens diverse portfolio of RNAi intellectual property

Silence Therapeutics deepens diverse portfolio of RNAi intellectual property

EPO rules in favor of Alnylam Pharmaceuticals’ Kreutzer-Limmer '945 patent

EPO rules in favor of Alnylam Pharmaceuticals’ Kreutzer-Limmer '945 patent